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NOVEL METHOD OF ADMINISTERING
B-BLOCKERS AND NOVEL DOSAGE FORMS
CONTAINING SAME

selected B-blocker is employed in the instant composi
tions and method in the pharmaceutically acceptable

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a novel method of

administering selected known adrenergic B-receptor
blocking agents, and to novel dosage forms containing
such agents adapted for nasal administration.
2. Background Art
A number of B-adrenergic blocking agents are

2

ride, alprenolol hydrochloride, metoprolol tartrate,
nadoxolol hydrochloride, pamatolol sulfate, timolol
maleate, bupranolol hydrochloride, etc.); generally, the
form which has previously been found most advanta
geous for oral or intravenous use. The structural formu
10

lae for the free bases encompassed by the present inven
tion are set forth below:
dichloroiso-

known. Such agents are widely used therapeutically, ' proterenol Cl
chie?y in the management of hypertension and in the 15
treatment of angina pectoris, arrhythmias and other
Cl
cardiac conditions, and also possibly in the treatment of
migraine. Unfortunately, however, these known B
pronethalol
blockers are inef?ciently and variably absorbed from
oral dosage forms, probably because of extensive‘ me

tabolism of the drug in the gastrointestinal tract and/or
extensive effects of the ?rst pass through the liver.
The present inventor and his co-workers have previ
ously reported that one widely used B-blocker, pro
pranolol, can be effectively administered in nasal dos
age form. Nasal administration of propanolol has been
found to provide enhanced bioavailability and mini
mized variations in blood levels as compared to oral
administration. See copending Hussain et a1.‘ Applica
tion Ser. No. 063,176, ?led Aug. 3, 1979; Hussain et al.
J. Pharm. Sci., Vol. 68, No. 8, September, 1979, page

yet other adrenergic B-receptor blocking agents can be
effectively administered nasally. More speci?cally, the
present inventor has found that selected B-blockers,

nciicmNHcmcl-mz
0H

(|)H

oxprenolol

0H

OCH2CH=CH2

pindolol

Iii

35

N

OCH2(‘:HCH2NHCH(CH3)2

40

OH

metoprolol

I

cmocmcm-Q-ocr-lzcncnzNncmcnm

B-blocker receptor selectivity (B1 versus 3;), agonist
properties and/or membrane-stabilization activity] from
that of propanolol, can nevertheless be advantageously
formulated into novel nasal dosage forms and adminis
tered nasally to provide enhanced bioavailability and

OH

nadoxolol

,

OH

|

/NH2

OCl-I2CHCH2C\
.
\Non

minimized variations in blood levels as compared to
oral dosage forms of those B-blockers, while at the same
time providing relative ease of administration when
compared to the intravenous route. The novel nasal
dosage forms of the invention can be solutions, suspen

practolol

sions, ointments or gels adapted for nasal administra

(IJH

(Cl-I3)2CHNHCH2CHCH20—©—NI-I?CH;

55

O

DETAILED DESCRIPTION OF THE
INVENTION
butoxamine
The selected B-blockers for use in the compositions
and methods of the present invention are dichloroiso 60

cally acceptable form of these B-blockers can be em
ployed, i.e. the free base ora pharmaceutically accept
able salt or ester thereof (e.g., oxprenolol hydrochlo

’

OCH2CHCH2NHCH(CH3)2

biological pro?les [e.g., they may differ in potency,

proterenol (DCI), pronethalol, sotalol, oxprenolol, pin
dolol, metoprolol, nadoxolol, practolol, butoxamine,
alprenolol, metalol, nifenalol, acebutolol, atenolol,
bunolol, carteolol, labetalol, pamatolol, timolol, ti
prenolol, xipranolol and bupranolol. Any pharmaceuti

v

CHgSOgNH-Q- CHCH2NHCH(CH3)2

which differ substantially in chemical structure from
propanolol and which also have signi?cantly different

tion.

|

sotalol

1196; Hussain et al, J. Pharm. Sci, Vol. 69, No. 10,
October, 1980, page 1240; Hussain et al, J. Pharm. Sci,
Vol. 69, No. 12, December, 1980, pages 1411-1413.
SUMMARY OF THE INVENTION
Surprisingly, the present inventor has now found that

OH

CH3

HOCHCHNI-IC(CH3)3
OCH3

CH3O
65

alprenolol
OH
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4
-continued

-continued
metalol

xipranolol

OH

CH3

CH(|3HNHCH3 '

H1?

5

CH3

OH

ocmcncnmncmcm);

SOZCH3
nifenalol

(IJH

’

i

10

CH3

O2N—©—CHCH1NHCH(CH3)2
acebutolol

bupranolol

.

cocn;

CH3CH2CH2CONH

H3O

l5

OCH7_(l3HCH2Nl-ICH(CH3)2
0H

'

atenolol

20

(‘H-I
0CH1CHCH2NHCH(CH3)2

with results considerably superior to those obtained
with oral administration in terms of enhanced drug
25 bioavailability and minimization of blood level varia
tions, thus enabling use of these B-blockers at lower
dosage levels than was previously possible except in the

CHZCONHZ

bunolol

case of intravenous administration. It would appear that

(|)l-_l

CED-ocmcncnmnqc?a);
ll

'

30

these selected B-blockers are rapidly absorbed from the
nasal mucosa into systemic blood without ?rst-pass
metabolism.

‘

0

carteolol

These B-blockers can be made by well-known methods.
In accord with the present invention, the selected
,B-blockers named supra can be administered nasally

>

Any of the selected B-blockers identi?ed above can
be conveniently administered nasally to warm-blooded
animals by formulating it into a nasal dosage form com

H

I

N

35 prising the desired B-blocker, in an effective B-blocking

¢O

amount, together with a nontoxic pharmaceutically
acceptable nasal carrier therefor. As indicated earlier,
the B-blocker can be employed in the form of the free
base or in the form of a pharmaceutically acceptable salt

0CH2CHCH2NHC(CH3)3

40 or ester thereof. Suitable nontoxic pharmaceutically

acceptable nasal carriers will be apparent to those
skilled in the art of nasal pharmaceutical formulations.
For those not skilled in the art, reference is made to the

OH

labetalol

CoNm

text entitled “REMINGTON’S PHARMACEUTI

OH

45

U-cmcmanmtcman
cit;

CAL SCIENCES”, 14th edition, 1970. Obviously, the
choice of suitable carriers will depend on the exact

nature of the particular nasal dosage form desired, e.g.,

0H

whether the B-blocker is to be formulated into a nasal
pamatolol

50 solution (for use as drops or as a spray), a nasal suspen
sion, a nasal ointment or a nasal gel. Preferred nasal

OCH2CHCH2NHCH(CH3)2
OH

dosage forms are solutions, suspensions and gels, which
contain a major amount of water (preferably puri?ed
water) in addition to the active ingredient. Minor
55 amounts of other ingredients such as pH adjusters (e.g.,

CHgCI-IgNHCOOCI-Ig
timolol

a base such as NaOH), emulsi?ers or dispersing agents,

S

N/ \N

buffering agents, preservatives, wetting agents and jell
ing agents (e.g., methylcellulose) may also be present.

OH
I

/ \ N)I——-H—OCH2CHCH2NHC(CH3)3
O

Most preferably, the nasal composition is isotonic, i».e. it
60 has the same osmotic pressure as blood serum; If de

sired, sustained release nasal compositions,‘ e.g. sus~
tiprenolol

tained release gels, can be readily prepared, preferably
by employingthe desired‘ B-blocker in 'one of its rela

OH
OCHZCHCHZNHCKKCHQZ

: is-cn;

tively insoluble forms, such as the free base or an insolu?
'‘

65

ble salt.v When the free base is not suf?ciently insoluble
for sustained release compositions, or when a more

highly insoluble form is desired, a long chain carboxylic
acid salt of the desired B-blocker can be conveniently

5

4,428,883

6

employed. The carboxylic acid portion of the salt pref

Repetition of the foregoing procedure utilizing 8

erably contains 10 to 20 carbon atoms. Such salts (e.g.

grams of sotalol in place of the dichloroisoproterenol
affords a nasal composition containing 8 mg of sotalol

stearates, palmitates etc.) can be readily synthesized, for
example, by dissolving the hydrochloride salt of the

per 0.1 ml.

B-blocker in water, then adding the alkali metal salt of

The procedure of the ?rst paragraph of this example
is substantially repeated, save that 5 grams of pindolol
are employed in place of the dichloroisoproterenol, to
afford a nasal composition containing 5 mg of pindolol

the desired long chain carboxylic acid (e.g. sodium

stearate). The corresponding long chain carboxylic acid
salt which precipitates out of solution is removed by
?ltration. Alternatively, equimolar amounts of the B

per 0.1 ml.

blocker free base and the long chain carboxylic acid are 0
combined in methanol. That mixture is then added to a

small volume of water, causing the desired salt (e.g.
B-blocker stearate) to precipitate out.

EXAMPLE 4
80 Grams of water are heated to 80° C. and 3.0 grams

of Methocel are added, with stirring. The resultant

Examples of the preparation of typical nasal composi

mixture is allowed to stand at room temperature for 3
hours. Then, 1.84 grams of oxprenolol stearate are sus
pended in 20 grams of water, that suspension is added to

tions containing selected B-blockers are set forth below.
However, it is to be understood that these examples are
given by way of illustration only and are not to be con
strued as limiting the invention either in spirit or in

the gel and thoroughly mixed, and the resultant viscous
solution or gel is adjusted to isotonicity with sodium
chloride. The sustained release composition thus ob

scope as many modi?cations both in materials and in
20
methods will be apparent to those skilled in the art.
tained contains 1.84 mg of oxprenolol stearate per 0.1
ml.
EXAMPLE 1

The above procedure is substantially repeated, except

2 Grams of sotalol hydrochloride are dissolved in 80
ml of distilled water and the pH of the resultant solution

is adjusted to 7.4 with dilute sodium hydroxide solution.
A quantity of water suf?cient to bring the total volume
to 100 ml is then added and suf?cient sodium chloride
or other appropriate salt is added to adjust the solution
to isotonicity. The solution is then sterilized by being
passed through a 0.2 micron Millipore ?lter. The ?nal
composition contains 2 mg of sotalol hydrochloride per
0.1 ml of solution.
The above procedure is repeated using 2 grams of
oxprenolol hydrochloride in place of the sotalol hydro
chloride. The resultant composition contains 2 mg of
oxprenolol hydrochloride per 0.1 ml of solution.

that 2.0 rather than 3.0 grams of Methocel are em

ployed, and 3.0 grams of sotalol palmitate are substi
tuted for the oxprenolol stearate. The sustained release
composition prepared in this manner contains 3.0 mg of
sotalol palmitate per 0.1 ml.
Repetition of the procedure of the ?rst paragraph of
this example, but using 2 grams of nadoxolol stearate in
place of the oxprenolol stearate, affords a sustained
release composition containing 2 mg of nadoxolol stea
rate per .\0.1 ml.
The procedure of the ?rst paragraph of this example
is
substantially repeated, except that 1.84 grams of di
35

chloroisoproterenol palmitate are employed in place of

the oxprenolol stearate. The resultant sustained release

Repetition of the procedure of the ?rst paragraph of
this example using 4 grams of metoprolol tartrate in

composition contains 1.84 mg of dichloroisoproterenol

water suf?cient to bring the total volume to 100 ml is
then added and suf?cient sodium chloride is added to

selected ,B-blockers suitable for use as nasal drops or

palmitate per 0.1 ml.
place of the sotalol hydrochloride affords a nasal com 40
Substitution of 20 grams of pronethalol myristate for
position containing 4 mg of metoprolol tartrate per 0.1
the oxprenolol stearate used in the ?rst paragraph of
ml of solution.
this example and substantial repetition of the procedure
there
detailed afford a sustained release composition
EXAMPLE 2
containing 20 mg‘ of pronethalol myristate per 0.1 ml.
15 Grams of alprenolol hydrochloride are combined 45
EXAMPLE 5
with 80 ml of distilled water and the pH is adjusted to
4.5 with dilute sodium hydroxide solution. A quantity of
The following are illustrative aqueous solutions of
nasal spray. In each case, the pH of the ?nal composi
adjust the solution to isotonicity. The solution is then 50 tion is adjusted to 7.4. If’ desired, the solutions are ad
sterilized by being passed through a 0.2 micron Mil
justed to isotonicity.
lipore ?lter. The resultant composition contains 15 mg
of alprenolol hydrochloride per 0.1 ml.

The procedure described above is substantially re-'
peated, except that 30 grams of pronethalol hydrobro 55

Ingredient

mide are used in place of the alprenolol hydrochloride,
affording a nasal composition containing 30 mg of
pronethalol hydrobromide per 0.1 ml.

nadoxol hydrochloride

EXAMPLE 3
4 Grams of dichloroisoproterenol are dissolved in 80
ml of isotonic saline solution and the pH of the resultant

solution is adjusted to 7.0-7.2 with dilute hydrochloric
acid. A quantity of isotonic saline suf?cient to bring the
total volume to 100 ml is then added, and the solution is 65
sterilized by being passed through a 0.2 micron Mil
lipore ?lter. The resultant composition contains 4 mg of
dichloroisoproterenol per 0.1 ml.

4

Amount

w
500 mg

Tween 80

2 mg

methylcellulose
water, puri?ed

20 mg
10 ml

w
bupranolol hydrochloride

750 mg

Tween 80

3 mg

methylcellulose
water, puri?ed

30 mg
7

10 ml

w
timolol maleate
Tween 80

methylcellulose
water, puri?ed

800 mg
'

3 mg

20 mg
10 ml

7,
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9. A pharmaceutically acceptable, sustained release
nasal composition, in dosage unit form, for nasal admin
istration to obtain a systemic therapeutic B-adrenergic

Naturally, the therapeutic dosage range for nasal
administration of the ,B-blockers according to the pres
ent invention will vary with the size of the patient, the
condition for which the drug is administered and the

blocking response in a warm-blooded animal, consisting

essentially of, per nasal dosage unit, (i) a systemically

particular B-blocker employed. Generally, the daily

therapeutically effective unit B-adrenergic blocking

dosage will approximate the amounts previously em
ployed for intravenous administration of the particular

amount of a long chain carboxylic acid salt of di

chloroisoproterenol, pronethalol, sotalol, oxprenolol,
pindolol, metoprolol, nadoxol, practolol, butoxamine,

,B-blocker involved. Thus, a typical dose of sotalol
would be 1 to 10 mg administered nasally three times

alprenolol, metalol, nifenalol, acebutolol, atenolol,
bunolol, carteolol, labetalol, pamatolol, timolol, ti

daily. The quantity of nasal dosage form needed to
deliver the desired dose will of course depend on the

prenolol, xipranolol or bupranolol, the carboxylic acid

concentration of B-blocker in the composition. The

portion of said salt containing 10 to 20 carbon atoms,
and (ii) a nontoxic pharmaceutically acceptable nasal
deliver the typical dose of sotalol speci?ed above would
15 carrier therefor, said composition being in the form of a
be 0.05 to 0.5 ml of 2% solution or gel.
volume of solution or gel which would be needed to

nasal ointment or a nasal gel.

While the invention has been described in terms of

said salt is a stearate.

appreciate that various modi?cations, substitutions,

11. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic
acid salt of dichloroisoproterenol.
12. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit [3
adrenergic blocking amount of a long chain carboxylic
acid salt of pronethalol.
13. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit [3
adrenergic blocking amount of a long chain carboxylic

omissions and additions may be made without departing
from the spirit thereof‘. Accordingly, it is intended that
the scope of the present invention be limited solely by
the scope of the following claims.
What is claimed is:
1. A method for eliciting a systemic therapeutic ,8
adrenergic blocking response in a warm-blooded ani

mal, which comprises nasally administering to said ani
mal a systemically therapeutically effective B-adrener
gic blocking amount of dichloroisoproterenol, prone

thalol, sotalol, oxprenolol, pindolol, metoprolol, nadox
olol, practolol, butoxamine, alprenolol, metalol, nifena
lol, acebutolol, atenolol, bunolol, carteolol, labetalol,
pamatolol, timolol, tiprenolol, xipranolol or bupranolol,

acid salt of sotalol.

14. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic
acid salt of oxprenolol.
15. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic
acid salt of pindolol.

or a nontoxic pharmaceutically acceptable salt thereof.
2. A method as de?ned by claim 1 for eliciting a

systemic therapeutic B-adrenergic blocking response in
a warm-blooded animal, which comprises nasally ad
ministering to said animal a systemically therapeutically
effective B-adrenergic blocking amount of dichloroiso

16. The composition as de?ned by claim 9, wherein

proterenol, pronethalol, sotalol, oxprenolol, pindolol,
alprenolol, metoprolol, nadoxolol, timolol or bu
pranolol, or a nontoxic pharmaceutically acceptable
acid addition salt thereof.
3. A method as de?ned by claim 1 for eliciting a ,

systemic therapeutic B-adrenergic blocking response in
a warm-blooded animal, which comprises nasally ad
ministering to said animal a systemically therapeutically
effective B-adrenergic blocking amount of a long-chain
carboxylic acid salt of dichloroisoproterenol, prone

' 18. The composition as de?ned by claim 9, wherein

(i) is a systemically therapeutically effective unit ,8
adrenergic blocking amount of a long chain carboxylic
acid salt of practolol.

4. A method for eliciting a systemic therapeutic B

comprises nasally administering to said animal, a sys

temically therapeutically effective B-adrenergic block
ing amount of a composition as de?ned.
5. A method as de?ned by claim 1, wherein said

warm-blooded animal is af?icted with angina pectoris.
6. A method as de?ned by claim 1, wherein said

warm-blooded animal is af?icted with arrhythmias.

-

19. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit ,8
adrenergic blocking amount of a long chain carboxylic

the carboxylic acid portion of said salt containing 10 to
adrenergic response in a warm-blooded animal which

(i) is a systemically therapeutically effective unit [3
adrenergic blocking amount of a long chain carboxylic
acid salt of metoprolol.
17. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic
acid salt of nadoxolol.

thalol, sotalol, oxprenolol, pindolol, metoprolol, nadox
olol, practolol, butoxamine, alprenolol, metalol, nifena
lol, acebutolol, atenolol, bunolol, carteolol, labetalol,
pamatolol, timolol, tiprenolol, xipranolol or bupranolol,
20 carbon atoms.

,

10. The composition as de?ned by claim 9, wherein

various preferred embodiments, the skilled artisan will

acid salt of butoxamine.

55

'

20. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic
acid salt of alprenolol.
21. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic
acid salt of metalol.
22. The composition as de?ned by claim 9, wherein

(i) is a systemically therapeutically effective unit B

7. A method as de?ned by claim 1, wherein said 65 adrenergic blocking amount of a long chain carboxylic
acid salt of nifenalol.
warm-blooded animal is afflicted with hypertension.
23. The composition as de?ned by claim 9, wherein
8. A method as de?ned by claim 1, wherein said
(i) is a systemically therapeutically effective unit B
warm-blooded animal is af?icted with migraine.

4,428,883
adrenergic blocking amount of a long chain carboxylic

39. The composition as de?ned by claim 35, wherein

acid salt of acebutolol.
24. The composition as de?ned by claim 9, wherein

(i) is a systemically therapeutically effective unit [3
adrenergic blocking amount of pronethalol or a non

(i) is a systemically therapeutically effective unit B~
adrenergic blocking amount of a long chain carboxylic
acid salt of atenolol.

-

toxic pharmaceutically acceptable acid addition salt
thereof.
40. The composition as de?ned by claim 35, wherein

'

25. The composition ‘as de?ned by claim 9, wherein

(i) is a systemically therapeutically effective unit [3

(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic

adrenergic blocking amount of sotalol or a nontoxic

acid salt of bunolol.

'

pharmaceutically acceptable acid addition salt thereof.
10

26. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic
acid salt of carteolol. -

'

adrenergic blocking amount of oxprenolol or a nontoxic

pharmaceutically acceptable acid addition salt thereof.
42. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit B

.

27. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of a long chain carboxylic
acid salt of labetalol.
28. The composition as de?ned by claim 9, wherein

(i) is a systemically therapeutically effective unit [3

41. The composition as de?ned by claim 35, wherein

(i) is a systemically therapeutically effective unit B

adrenergic blocking amount of pindolol or a nontoxic

pharmaceutically acceptable acid addition salt thereof.
20

43. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit B
adrenergic blocking amount of metoprolol or a non

adrenergic blocking amount of a long chain carboxylic
toxic pharmaceutically acceptable acid addition salt
acid salt of pamatolol.
29. The composition as de?ned by claim 9, wherein
44. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit [3
(i)
is a systemically therapeutically effective unit ,8
adrenergic blocking amount of a long chain carboxylic 25 adrenergic blocking amount of nadoxolol or a nontoxic
acid salt of timolol.
]
pharmaceutically acceptable acid addition salt thereof.
30. The composition as de?ned by claim 9, wherein
45. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit B ' (i) is a systemically therapeutically effective unit [3
adrenergic blocking amount of a long chain carboxylic
adrenergic blocking amount of practolol or a nontoxic
acid salt of tiprenolol.
.
~
pharmaceutically acceptable acid addition salt thereof.
31. The composition as de?ned by claim 9, wherein
46. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit B
(i) is a (systemically therapeutically effective unit B
adrenergicblocking amount of a long chain carboxylic
adrenergic blocking amount of butoxamine or a non
acid salt of xipranolol.
35 toxic pharmaceutically acceptable acid addition salt
32. The composition as de?ned by claim 9, wherein
(i) is a systemically therapeutically effective unit B
47. The composition as de?ned by claim 35, wherein
adrenergic blocking amount of a long chain carboxylic
(i) is a systemically therapeutically effective unit ,8
acid salt of bupranolol.
adrenergic blocking amount of alprenolol or a nontoxic _
33. The composition as de?ned by claim 9, said com~ 40 pharmaceutically acceptable acid addition salt thereof.
‘ position being in the form of a nasal ointment.
48. The composition as de?ned by claim 35, wherein
34. The composition as de?ned by claim 9, said com
(i) is a systemically therapeutically effective unit ,8
position being in the form of a nasal gel.
adrenergic blocking amount of metalol or a nontoxic
35. A pharmaceutically acceptable nasal composition,
pharmaceutically acceptable acid addition salt thereof.
in dosage unit form, for nasal administration to obtain a 45 49. The composition as de?ned by claim 35, wherein
systemic therapeutic B-adrenergic blocking response in
(i) is a systemically therapeutically effective unit B
a warm-blooded animal, consisting essentially of, per
adrenergic blocking amount of nifenalol or nontoxic
nasal dosage unit, (i) a systemically therapeutically ef
pharmaceutically acceptable acid addition salt thereof.
fective unit B-adrenergic blocking amount of di
50. The composition as de?ned by claim 35, wherein
chloroisoproterenol, pronethalol, sotalol, oxprenolol, (i) is a systemically therapeutically effective unit B
thereof.

thereof.

pindolol, metoprolol, nadoxolol, practolol, butoxamine,
alprenolol, metalol, nifenalol, acebutolol, atenolol,
bunolol, carteolol, labetalol, pamatolol, timolol, ti

'

i

.

adrenergic blocking amount of acebutolol or a nontoxic

pharmaceutically acceptable acid addition salt thereof.
51. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit B

prenolol, xipranolol or bupranolol, or a nontoxic phar
maceutically acceptable salt thereof, and (ii) a nontoxic

adrenergic blocking amount of atenolol or a nontoxic

pharmaceutically acceptable nasal carrier therefor, said

pharmaceutically acceptable acid addition salt thereof.

composition being in the form of a nasal ointment or a

52. The composition as de?ned by claim 35, wherein

nasal gel adapted for sustained release to the nasal mu

(i) is a systemically therapeutically effective unit B

cosa.

adrenergic blocking amount of bunolol or a nontoxic

36. The composition as de?ned by claim 35, said
pharmaceutically acceptable acid addition salt thereof.
composition being in the form of a nasal ointment.
53. The composition as de?ned by claim 35, wherein
37. The composition as de?ned by claim 35, said
(i) is a systemically therapeutically effective unit [3
composition being in the form of a nasal gel.
adrenergic blocking amount of carteolol or a nontoxic
38. The composition as de?ned by claim 35, wherein
pharmaceutically acceptable acid addition salt thereof.
(i) is a systemically therapeutically effective unit ,8 65 54. The composition as de?ned by claim 35, wherein
adrenergic blocking amount of dichloroisoproterenol or
(i) is a systemically therapeutically effective unit ,8
a nontoxic pharmaceutically acceptable acid addition
adrenergic blocking amount of labetalol or a nontoxic
salt thereof‘.
pharmaceutically acceptable acid addition salt thereof.

v
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adrenergic blocking amount of xipranolol or a nontoxic

55. The composition as de?ned by claim 35, wherein

pharmaceutically acceptable acid addition salt thereof.

(i) is a systemically therapeutically effective unit B

59. The composition as de?ned by claim 35, wherein

adrenergic blocking amount of pamatolol or a nontoxic

(i) is a systemically therapeutically effective unit ,8

pharmaceutically acceptable acid addition salt thereof.
56. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit B

adrenergic blocking amount of bupranolol or a nontoxic

adrenergic blocking amount of timolol or a nontoxic.

proterenol, pronethalol, sotalol, oxprenolol, pindolol,

pharmaceutically acceptable acid addition salt thereof.
57. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit ,8

metoprolol, nadoxolol, practolol, butoxamine, al
prenolol, metalol, nifenalol, acebutolol, atenolol, buno
lol, carteolol, labetalol, pamatolol, timolol, tiprenolol,
xipranolol or bupranolol, the carboxylic acid portion of

pharmaceutically acceptable acid addition salt thereof.
60. A long chain carboxylic acid salt of dichloroiso

adrenergic blocking amount of tiprenolol or a nontoxic

said salt containing 10 to 20 carbon atoms.
61. A salt as de?ned by claim 60, said salt being a

pharmaceutically acceptable acid addition salt thereof.
58. The composition as de?ned by claim 35, wherein
(i) is a systemically therapeutically effective unit [3

stearate.
*

20

25

35

45

50

v55

65

=lr

*

*

*

